News coverage about Echo Therapeutics (NASDAQ:ECTE) has trended somewhat positive on Monday, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Echo Therapeutics earned a news impact score of 0.05 on Accern’s scale. Accern also assigned news stories about the medical device company an impact score of 44.7602333626618 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of Echo Therapeutics (NASDAQ ECTE) remained flat at $0.04 during mid-day trading on Monday. 1,050 shares of the stock traded hands. The company has a 50-day moving average of $0.05 and a 200 day moving average of $0.08. Echo Therapeutics has a one year low of $0.04 and a one year high of $0.93.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at

Echo Therapeutics Company Profile

Echo Therapeutics, Inc is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment.

Receive News & Stock Ratings for Echo Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Echo Therapeutics Inc and related stocks with our FREE daily email newsletter.